Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03331198 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
A Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Small Lymphocytic, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT03331198: Recruiting Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Small Lymphocytic, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
NCT03331198 is a Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Small Lymphocytic that is actively recruiting participants, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 320 participants, below the 462-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03331198, a Phase 1 study of Leukemia, Lymphocytic, Chronic, B-Cell and Lymphoma, Small Lymphocytic, is actively recruiting participants, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.
Primary Outcome
Proportion of subjects experiencing adverse events
Conditions Studied
Interventions
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel)
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel) + ibrutinib
- BIOLOGICAL JCAR017 (lisocabtagene maraleucel) + venetoclax
Study Locations (20)
California
- City of Hope - Duarte
- City Of Hope - Duarte
- UC San Diego Moores Cancer Center - La Jolla
- University Of California San Diego Moores Cancer Center - La Jolla
- Local Institution - 0059 - Los Angeles
- University of California, Los Angeles - Los Angeles
- Local Institution - 0010 - San Francisco
- University of California, San Francisco - San Francisco
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama Birmingham - Birmingham
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Banner MD Anderson Cancer Center - Gilbert
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- Local Institution - 0085 - Washington D.C.
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Mayo Clinic - Jacksonville
Georgia
- Local Institution - 0104 - Atlanta
- Local Institution - 0019 - Atlanta
Colorado
- Colorado Blood Cancer Institute - Denver
Delaware
- Local Institution - 0110 - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2027-11-26 |
| Phase | Phase 1 |
What NCT03331198 shows while recruiting
NCT03331198 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 462-participant average among 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials with a reported enrollment target (31% lower).
The record links to 2 conditions, with Leukemia, Lymphocytic, Chronic, B-Cell appearing as the primary indexed condition, and to 3 interventions - of which JCAR017 (lisocabtagene maraleucel) is the first listed.
NCT03331198 names 20 study sites across 8 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03331198 about?
NCT03331198 is a clinical study titled "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)". This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or S...
What is the current status of trial NCT03331198?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2017-11-27. Estimated completion is 2027-11-26.
What conditions does trial NCT03331198 study?
This clinical trial studies the following conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic.
What interventions are being tested in trial NCT03331198?
The interventions under investigation include: JCAR017 (lisocabtagene maraleucel) (BIOLOGICAL), JCAR017 (lisocabtagene maraleucel) + ibrutinib (BIOLOGICAL), JCAR017 (lisocabtagene maraleucel) + venetoclax (BIOLOGICAL).
Who is sponsoring clinical trial NCT03331198?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03331198 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Lymphocytic, Chronic, B-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03331198's enrollment target sits among peer trials
320 3rd of 11 higher than 8 of 11 other Leukemia, Lymphocytic, Chronic, B-Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia, Lymphocytic, Chronic, B-Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
RECRUITING · Phase 1
-
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
ACTIVE NOT RECRUITING · Phase 1
-
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
COMPLETED · Phase 1
-
Family Study of Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- NCT04606446 · 320 participants · Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI